

Special Issue

Fibromyalgia and Neuroinflammation: Unraveling Pathophysiological Links and Therapeutic Targets

Message from the Guest Editor

Fibromyalgia is a complex, chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, cognitive disturbances, and mood disorders.

This Special Issue aims to explore the emerging connection between fibromyalgia and neuroinflammatory processes. We invite original research articles, comprehensive reviews, and translational studies that investigate the role of neuroinflammation in the pathogenesis, diagnosis, and treatment of fibromyalgia. Topics of interest include, but are not limited to, the following:

- Microglial and astrocyte activation in fibromyalgia;

- Cytokine and chemokine profiles in patients with fibromyalgia;

- Neuroimmune mechanisms underlying central sensitization;

- Neuroimaging markers of inflammation in fibromyalgia;

- The gut–brain axis and systemic inflammation in fibromyalgia;

- Role of oxidative stress and mitochondrial dysfunction;

- Preclinical models of fibromyalgia with a focus on neuroinflammatory markers;

- Novel anti-inflammatory therapies targeting neuroimmune pathways;

- Biomarkers for diagnosis and disease progression;

- Interplay between neuroinflammation and psychiatric comorbidities.

Guest Editor

Dr. Mario García-Domínguez

Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, 31008 Pamplona, Spain

Deadline for manuscript submissions

30 November 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/247308

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).